Cytokinetics Incorporated (CYTK)
NASDAQ: CYTK · Pharmaceutical Preparations · South San Francisco, CA
Our rating: Positive
Call changed from Cautious to Positive at $55.55, moderate conviction, November 5, 2026.
Breaks if: The Positive view rests on the commercial revenue ramp sustaining momentum. It would be proved wrong if revenue growth decelerates to below 80% year-over-year in either of the next two quarterly reports — a level that would signal the launch is losing steam well before the revenue base can support the valuation — or if the annualized FCF burn rate rises above $700 million for any single reported quarter within the next twelve months, implying cost escalation has outrun the top line. Either condition would call the duration of the runway into serious question and shift the balance of evidence toward Cautious.
Key figures
| Market value | $7.1B |
|---|---|
| Revenue, last 12 months | $113M |
| Net income, last 12 months | −$778M |
| Free cash flow, last 12 months | −$589M |
| Price to earnings | n/a |
| Free cash flow yield | −8.3% |
| Dividend yield | 0.0% |
| Operating margin | −625.2% |
| Return on equity | n/a |
| Beta to the S&P 500 | 0.83 |
| Volatility, annualized | 53.7% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $48M | 2356.5% | $-1.37 | −$125M |
| June 30, 2026 | $29M | −57.1% | $-1.50 | −$164M |
| March 31, 2026 | $19M | 1125.8% | $-1.67 | −$151M |
| December 31, 2025 | $18M | 4.9% | $-1.50 | −$148M |
| September 30, 2025 | $2M | 318.1% | $-2.55 | −$117M |
| June 30, 2025 | $67M | 26714.9% | $-1.12 | −$132M |
| March 31, 2025 | $2M | 89.1% | $-1.36 | −$137M |
| December 31, 2024 | $17M | 912.4% | $-1.26 | −$67M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $0.17B: Claude 8%, Gemini 15%, Mistral 7%
- Diluted earnings per share are above zero: Claude 2%, Gemini 5%, Mistral 3%
- Free cash flow for the quarter is above zero: Claude 2%, Gemini 5%, Mistral 4%
16 ledger entries and 28 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.